osteoarthritis

What is “CARTISTEM” used for treatment of Hiddink?

Selected as a conducting company of ‘global high-tech biomedicine industry’

MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’

US ‘Stem cells regenerative medicine congress’ invites MEDIPOST for the first time as a Korean company

‘CARTISTEM’ shows superb results from 3 year long term tracking clinical trials

‘CARTISTEM’ injection to U.S. clinical trial subject completed

U.S. ABC News gave intensified coverage on ‘CARTISTEM’

Participation in Biotec Japan and local publicity activities on CARTISTEM

Accumulated Dosage of CARTISTEM Exceeds 2,000 Cases

Nikkei Japan Reports the Status of MEDIPOST’s Stem Cell Research

43% Increase in Dosage of CARTISTEM, for 4th Quarter of 2014 Year on Year

MEDIPOST will set up a joint venture company in China